Phlexglobal US expansion continues with Philadelphia office launch

Phlexglobal,the leading support contract research organization for TMF and eTMF management, has announced its expansion across the United States with the opening of an office in Philadelphia, Pennsylvania.

Phlexglobal's expansionacross the US follows thesuccess enjoyed by the organization's California office which has seen exponential demand for its services across the North Americanterritory. 

The opening of the Philadelphia office comeshot on the heels of April's management buy out (MBO) of the company by UKprivate equity firm Inflexion, which will allow Phlexglobal to further expand its provision of clinical trial support, underpinnedby the recent launch of version 3 of the company's eTMF solution,PhlexEview.

The new East Coast office,which will deliver all Phlexglobal's TMF services including theinnovative PhlexEview eTMF solution, will initially employ 20 staff, growing to50 employees within the first year of operation.

In addition to providing abase for Phlexglobal's resource solutions and operations task force, the800 square metre office will also house a new records centre, securely storinglive TMF documents for Phlexglobal clients acrossthe United States.

StellaDonoghue, Phlexglobal managing director, said: "The launch of a second officeonly a year after arriving in the US signals how rapidly Phlexglobalhas established itself as a major player in the North American market. 

"Thisis an exciting time for Phlexglobal - the launch of a second US office coupled with the recent MBO willprovide a valuable platform for the company to move into new markets includingAsia-Pacific, while still maintaining a strong presence in the UK and North America."

Phlexglobalis a specialist global CRO which delivers unique clinical research supportsolutions to meet its clients' needs through its five core services ofresourcing, task force, clinical support services, eTMF & documentsolutions and training. It works across the pharmaceutical, biotechnology,medical device, CRO and healthcare industries and counts 17 of the top 20global pharmaceutical companies amongst its clients.

Formore information on Phlexglobal's range of services visit www.phlexglobal.com

Suggested Articles

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.